Non-classic deubiquitinase USP13 inhibits bladder cancer metastasis through destabilizing cytoplasmic KDM3A
- PMID: 40253486
- DOI: 10.1038/s41388-025-03410-3
Non-classic deubiquitinase USP13 inhibits bladder cancer metastasis through destabilizing cytoplasmic KDM3A
Retraction in
-
Retraction Note: Non-classic deubiquitinase USP13 inhibits bladder cancer metastasis through destabilizing cytoplasmic KDM3A.Oncogene. 2025 Sep;44(33):3041. doi: 10.1038/s41388-025-03520-y. Oncogene. 2025. PMID: 40738967 No abstract available.
Abstract
Bladder cancer (BLCa) metastasis is a predominant cause of death for bladder cancer patients. Histone demethylase KDM3A specifically removes the repressive mono- or di-methyl marks from H3K9 and thus contributes to the activation of gene transcription. However, the underlying mechanisms of KDM3A in bladder cancer are poorly understood. Here, we report that high levels of KDM3A are associated with bladder cancer clinical progression. KDM3A silencing inhibits bladder cancer cell growth, cell migration and invasion in vitro and in vivo. Mechanistically, we identify that non-classic deubiquitinase USP13 interacts with KDM3A to promote its degradation in cytoplasm via the proteasome-specific pathway. USP13 was significantly down-regulated in bladder cancer tissues and negatively associated with KDM3A expression. Furthermore, we show in bladder injected-liver metastasis xenograft model that USP13 inhibits bladder cancer metastasis through destabilizing cytoplasmic KDM3A. Collectively, our findings identify KDM3A is an important regulator of bladder cancer cell growth and metastasis and targeting USP13/KDM3A complex could be a valuable strategy to ameliorate bladder cancer progression and metastasis.
© 2025. The Author(s), under exclusive licence to Springer Nature Limited.
Conflict of interest statement
Competing interests: The authors declare no competing interests.
References
-
- Horn SR, Stoltzfus KC, Lehrer EJ, Dawson LA, Tchelebi L, Gusani NJ, et al. Epidemiology of liver metastases. Cancer Epidemiol. 2020;67:101760. - PubMed
-
- Bouchelouche K. PET/CT in Bladder Cancer: An Update. Semin Nucl Med. 2022;52:475–85. - PubMed
-
- Witjes JA, Bruins HM, Cathomas R, Compérat EM, Cowan NC, Gakis G, et al. European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79:82–104. - PubMed
-
- Crabb SJ, Douglas J. The latest treatment options for bladder cancer. Br Med Bull. 2018;128:85–95. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- 82460497/National Natural Science Foundation of China (National Science Foundation of China)
- 82172921/National Natural Science Foundation of China (National Science Foundation of China)
- Grant No. 82260500/National Natural Science Foundation of China (National Science Foundation of China)
- Grant No. 20242BAB26142/Natural Science Foundation of Jiangxi Province (Jiangxi Province Natural Science Foundation)
- Grant No.20232ACB216014/Youth Science Foundation of Jiangxi Province (Youth Science Foundation of Jiangxi)
LinkOut - more resources
Full Text Sources
Medical
